Details for New Drug Application (NDA): 207475
✉ Email this page to a colleague
NDA 207475 describes AZACITIDINE, which is a drug marketed by Accord Hlthcare, Actavis Llc, Amneal, Cipla, Dr Reddys, Eugia Pharma, Eurohlth Intl Sarl, Hetero Labs Ltd Vi, Jiangsu Hansoh Pharm, Lupin Ltd, Meitheal, Msn Labs Pvt Ltd, Natco Pharma Ltd, Norvium Bioscience, and Shilpa Medicare, and is included in fifteen NDAs. It is available from seventeen suppliers. Additional details are available on the AZACITIDINE profile page.
The generic ingredient in AZACITIDINE is azacitidine. There are fifteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the azacitidine profile page.
The generic ingredient in AZACITIDINE is azacitidine. There are fifteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the azacitidine profile page.
Summary for 207475
| Tradename: | AZACITIDINE |
| Applicant: | Accord Hlthcare |
| Ingredient: | azacitidine |
| Patents: | 0 |
Pharmacology for NDA: 207475
| Mechanism of Action | Nucleic Acid Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for 207475
Suppliers and Packaging for NDA: 207475
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 207475 | ANDA | Accord Healthcare Inc. | 16729-306 | 16729-306-10 | 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (16729-306-10) |
| AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 207475 | ANDA | BluePoint Laboratories | 68001-527 | 68001-527-54 | 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (68001-527-54) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS, SUBCUTANEOUS | Strength | 100MG/VIAL | ||||
| Approval Date: | Jul 2, 2018 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
